Implicit’s anti-CD14 MAb heads to the U.S. in NIH COVID-19 phase II trial April 20, 2021 By Tamra Sami No Comments PERTH, Australia – Implicit Bioscience Ltd.’s lead candidate, IC-14, is the first anti-CD14 monoclonal antibody (MAb) to progress to the clinic as it enters a phase II trial in the U.S. in COVID-19 patients. Read More